AEON Biopharma
AEON
72 hedge funds and large institutions have $207M invested in AEON Biopharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 9 closing their positions.
73% more capital inflows, than outflows
Capital inflows: $33.6M | Capital outflows: $19.5M
5.25% more ownership
Funds ownership: 71.57% → 76.82% (+5.3%)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
1% less funds holding
Funds holding: 73 → 72 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aristeia Capital
Greenwich,
Connecticut
|
+$9.7M |
| 2 |
Sculptor Capital
New York
|
+$4.67M |
| 3 |
Saba Capital Management
New York
|
+$4.21M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.47M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$4.48M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$2.76M |
| 3 |
Mangrove Partners
Greenwich,
Connecticut
|
-$2.06M |
| 4 |
Arena Capital Advisors
Los Angeles,
California
|
-$1.84M |
| 5 |
JP Morgan Chase
New York
|
-$1.66M |
AEON Hedge Fund Activity: Q1 2022 in Review
72 of the 6,365 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2022, worth a combined $207M — up 8% from $192M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AEON and 8 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 13 added.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $9.7M. The largest seller was Blackstone Inc, cutting an estimated $4.48M.
- 72 institutional investors held AEON Biopharma (AEON) as of Q1 2022, down from 73 in Q4 2021.
- Funds reported $207M of AEON Biopharma stock for Q1 2022, up 8% quarter-over-quarter.
- 8 funds opened new AEON Biopharma positions in Q1 2022 and 9 closed out, a net change of -1 holder.
- The largest AEON Biopharma buyer in Q1 2022 was Aristeia Capital, an estimated $9.7M added.
- The largest AEON Biopharma seller in Q1 2022 was Blackstone Inc, an estimated $4.48M sold.
Based on aggregated 13F filings for Q1 2022.